Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-181c
Specific or universal ncRNAs
Specific ncRNAs
Class
MicroRNA
Biomarker
Yes
Biomarker application
Treatment
Upstream regulatory factors
Not available
Downstream target
WIF1
Cancer name
Non-Small Cell Lung Cancer
Cancer site
Lung
Treatment type
Chemotherapy
Drug
Cisplatin
Impact of wild-type ncRNA on chemotherapy resistance
Up
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
MiR-181c contributed to DDP resistance in NSCLC cells through activation of the Wnt/Ī²-catenin pathway by targeting WIF1.
Tissue resource
lung cancer tissues and matched adjacent normal tissues
human non-small cell lung cancer cell lines A549
human non-small cell lung cancer cell lines H1299
human bronchial epithelial cell lines HBE
human non-small cell lung cancer cisplatin-resistant cell lines A549/DDP
human non-small cell lung cancer cisplatin-resistant cell lines H1299/DDP
Experiment
qRT-PCR,Western blot,Dual-luciferase reporter assay
Institute
Huaihe Hospital of Henan University
Cell Bank of the Chinese Academy of Sciences
Country
China
Continent
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.